Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial

Kathryn E. Stephenson, Chen Sabrina Tan, Stephen R. Walsh, Andrew Hale, Jessica L. Ansel, Diane G. Kanjilal, Kate Jaegle, Lauren Peter, Erica N. Borducchi, Joseph P. Nkolola, Tatenda Makoni, Rachel Fogel, Connor Bradshaw, Anna Tyler, Edward Moseley, Abishek Chandrashekar, Katherine E. Yanosick, Michael S. Seaman, Kenneth H. Eckels, Rafael A. De La BarreraJason Thompson, Peter Dawson, Stephen J. Thomas, Nelson L. Michael, Kayvon Modjarrad, Dan H. Barouch*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences